Wedbush Reaffirms “Outperform” Rating for Apogee Therapeutics (NASDAQ:APGE)
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a report released on Monday morning,RTT News reports. They currently have a $90.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in […]
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a report released on Monday morning,RTT News reports. They currently have a $90.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in […]
